XRCC1 and prostate cancer: When these studies were excluded, the result of XRCC1 Arg399Gln was changed among prostate cancer (recessive model: OR = 1.18, 95% CI = 1.04–1.35, Ph = 0.209, I2 = 21.5%), as shown in Table 5.